Alzheimer's disease therapeutics: new approaches to an ageing problem

David H Small, Dusan Losic, Lisandra Lorraine Martin, Bradley J Turner, Anna Friedhuber, Marie Isabel Aguilar

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)


Abnormal proteinaceous deposits are found in the brain of patients with many different neurodegenerative diseases. In many of these diseases, the production of the deposits is probably associated with disease pathogenesis. In Alzheimer s disease (AD), the amyloid protein (A beta), is produced by the action of enzymes known as secretases, which cleave the beta-amyloid protein precursor. A beta is secreted from cells in the brain, after which it oligomerizes and is deposited in the extracellular compartment of the brain to form amyloid plaques and amyloid angiopathy. Targeting the production of A beta and its aggregation is now a key strategy in the development of novel therapeutic agents for the treatment of AD. This review examines the potential of immunization strategies, cholesterol-lowering drugs, protease inhibitors and nicotinic drugs for the treatment of AD.
Original languageEnglish
Pages (from-to)203 - 208
Number of pages6
JournalIUBMB Life
Issue number4
Publication statusPublished - 2004

Cite this